The GI drug column. The ACG committee on FDA related matters.
D000464:Alginates / Q000627:therapeutic use; D000536:Aluminum Hydroxide / Q000009:adverse effects / Q000627:therapeutic use; D000863:Antacids / Q000009:adverse effects / Q000627:therapeutic use; D001639:Bicarbonates / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D002635:Chenodeoxycholic Acid / Q000009:adverse effects / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use; D004025:Dicyclomine / Q000627:therapeutic use; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D008276:Magnesium Hydroxide / Q000009:adverse effects / Q000627:therapeutic use; D012824:Silicic Acid / Q000627:therapeutic use; D012841:Simethicone / Q000009:adverse effects / Q000627:therapeutic use; D017693:Sodium Bicarbonate; D014481:United States; D014486:United States Food and Drug Administration
D000464:Alginates; D000863:Antacids; D001639:Bicarbonates; D004338:Drug Combinations; C008570:aluminum hydroxide, magnesium hydroxide, simethicone drug combination; D002635:Chenodeoxycholic Acid; D012824:Silicic Acid; D004025:Dicyclomine; D000536:Aluminum Hydroxide; C007829:alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination; D002927:Cimetidine; D012841:Simethicone; D017693:Sodium Bicarbonate; D008276:Magnesium Hydroxide